Over the last two decades, scientific developments have enhanced our understanding of the
pathogenesis of cardiovascular disease in patients with CKD, and specific nontraditional risk …

Sevelamer, has been shown to have many pleiotropic actions on lipid panel, various
inflammatory markers, and blood glucose levels in chronic kidney disease patients. We …

Background and Objectives: Abnormal arterial stiffness (AS) is a major complication in end-
stage kidney disease (ESKD) patients treated by dialysis. Our study aimed to determine the …

Abstract Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a
strong predictor of mortality in dialysis patients. FGF23 has been proposed as an early …

The researchers found that raised plasma levels of FGF23 were strongly associated with all-
cause mortality, cardiovascular events and progression to chronic dialysis. This association …

Background: The aim of the study was to assess the relationship between fibroblast growth
factor-23 (FGF-23) and vascular calcifications (VC) in peritoneal dialysis (PD) patients …

Background. Fibroblast growth factor (FGF)-23, a novel bone-derived phosphaturic factor
involved in mineral metabolism, is increased in chronic kidney disease (CKD); in dialysis …

Elevated plasma levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23)
are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows …

Aim Serum levels of 32 kDa-phosphaturic hormone fibroblast growth factor 23 (FGF23) rise
early in renal failure in order to keep phosphatemia within the normal range; however, this …

Background Endothelial dysfunction is the primary step for the development of CKD-related
cardiovascular disease. Early prediction and management can influence patient survival …